Vanguard Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.1M Buy
2,109,962
+22,669
+1% +$185K ﹤0.01% 2232
2026
Q2
$20.7M Buy
2,087,293
+172,865
+9% +$1.45M ﹤0.01% 2431
2026
Q1
$11.7M Buy
+1,914,428
New +$15.9M ﹤0.01% 2641

Other funds holding DNA

Vanguard Capital Management's DNA Position: Q3 2026 in Review

Vanguard Capital Management increased its Ginkgo Bioworks (DNA) stake by 1.1% in Q3 2026, buying an estimated $185K and bringing the position to 2,109,962 shares worth $27.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

Vanguard Capital Management first reported a position in DNA in Q1 2026 and has held it in 3 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Vanguard Capital Management held 2,109,962 shares of Ginkgo Bioworks worth $27.1M as of Q3 2026.
  • Vanguard Capital Management bought 22,669 Ginkgo Bioworks shares in Q3 2026, an estimated $185K.
  • Ginkgo Bioworks made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2232 holding.
  • Vanguard Capital Management first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 3 quarters since.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.